Breath Analysis
BREATH CAPTURE RESEARCH & TECHNOLOGY
patent pending
Just Breathe...
Non-invasive
Early Disease Detection
Point-of-Care Technology
Cost Effective
BREATH ANALYSIS
HOW IT WORKS
WHY IT MATTERS
Non-invasive
Early Disease Detection
Point-of-Care Technology
Cost Effective
Imagine a world where your breath could detect your health issues non-invasively. All that you have to do is
Just Breathe...
Hygieia Sciences is making this a reality through the use of research and technologies.
patent pending
The patient breathes into a breath capture device. It is then analyzed for early disease detection screening. By identifying and tracking patterns for inflammatory metabolic processes with multiple breath volatile organic compound (BVOC) fingerprints, Hygieia Sciences has proven success in distinguishing Breast Cancer, Lung Cancer, Parkinson's Disease, and Alzheimer's Disease in early stages.
More time for you and with your loved ones is the ultimate goal of our non-invasive, breath capture, early disease detection methods. Being able to identify diseases in some of the earliest stages, which are normally asymptomatic and undiagnosed by the medical profession today, give you or your loved ones a chance for treatment and medical intervention sooner.
​
Through the easy collection of a patient's breath using Hygieia Sciences' patented pending Breath Sampling Device, accurate and cost effective gains are made for the medical industry, which is ultimately passed on to the patient. This is a revolutionary disrupter for the traditional medical testing industry, not requiring the collection of blood, urine, or other specimens, minimizing patient inconvenience and potential use during routine medical screenings.
EARLY DETECTION
classifying Breast Cancer and a combined study mix of lung and breast cancer differentiation with 88% accuracy
classifying Parkinson's Disease from controls among the study group, resulting in 73.5% accuracy for total unknowns, which will continue to increase with additional population studies.
classifying Alzheimer's mild cognitive (MCI) from controls resulting in 85% accuracy for total unknowns.
100%
Accuracy
98%
Accuracy
95%
Accuracy
For more information, please contact us.
